Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

ABSTRACT: Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

PROVIDER: PRJNA1064872 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Global transcriptomics analysis for TDO2 alteration in human triple-negative breast cancer cell lines

Project description:To elucidate the downstream transcriptomics changes in reponse to TDO2 alteration including shRNA knockdown, overexpression and TDO2/IDO duak inhibitor treatments in human triple-negative breast cancer cell lines.

2025-01-02 | GSE253237 | GEO

Spatial transcriptomics of triple negative breast cancer

Project description:Spatial transcriptomics of triple negative breast cancer

| PRJNA866496 | ENA

Global phosphotyrosine survey reveals activation of multiple tyrosine kinase signaling pathways in triple negative breast cancer

Project description:About 15-20% of all breast cancers are triple negative breast cancers, which are often highly aggressive. We performed global quantitative phosphotyrosine profiling of a large panel of triple negative breast cancer cell lines using high resolution Fourier transform mass spectrometry. Our study identified 1,903 tyrosine-phosphorylated peptides derived from 969 proteins. Heterogeneous activation of tyrosine kinases was observed in triple negative breast cancer derived cell lines.

2016-07-06 | PXD001222 | Pride

Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer

Project description:Alteration of DNMT1/DNMT3A by eribulin elicits global DNA methylation changes with potential therapeutic implications for triple-negative breast cancer

| PRJNA983438 | ENA

miRNA sequencing on triple negative breast cancer cell lines

Project description:This study consists of miRNA seq data of 26 triple negative breast cancer cell lines

2018-02-07 | GSE108286 | GEO

Proteomic analysis of triple negative breast cancer cell lines

Project description:We analysed aquired chemotherapeutic resistance of two different triple negative breast cancer cell lines BT-549 (Doxorubicin resistance) and MDA-MB-468 (5-Fluorouracil) by comparing the proteome of the parental cell line with the resistant cell line.

2018-02-23 | PXD008522 | Pride

Triple therapy reduced metastasis in triple-negative breast cancer.

Project description:Triple therapy reduced metastasis in triple-negative breast cancer.

| PRJNA832953 | ENA

Spatial transcriptomics of triple negative breast cancer

Project description:Triple negative breast cancer (TNBC) is an aggressive and clinically challenging subtype of breast cancer. TNBC disporportionately affects African-American (AA) women, but the biological basis of this disparity is not understood. To gain a better understanding of TNBC, particularly in AA patients, we applied spatial transcriptomics to thoroughly characterize gene expression and tissue architecture in TNBC. Our cohort consisted of 22 patients, 15 of whom were AA, and 7 who were Caucasian. We obtained 2 sections from each patient's tumor (except for patient 19) for a total of 43 samples.

2022-11-02 | GSE210616 | GEO

miRNA sequencing on triple negative breast cancer cell lines

Project description:miRNA sequencing on triple negative breast cancer cell lines

| PRJNA423034 | ENA

Triple Negative Breast tumors: SPARC Positive Tumors vs SPARC Negative Tumors

Project description:The aim of this study was evaluate the transcriptome changes in the comparison between triple negative tumors with increased SPARC expression and triple negative tumors with decreased SPARC expression according to Nagai et al., 2011 (Breast Cancer Res Treat (2011) 126:1–14) The results generated could be of particular interest to better define the prognostic impact of SPARC expression in triple negative breast tumors

2018-07-01 | GSE98931 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data